Celsus Therapeutics, Plc

Celsus Therapeutics, Plc Celsus Therapeutics is a drug development company focusing on novel anti-inflammatory, first-in-class synthetic drugs.

Celsus Therapeutics is a drug development company focusing on novel anti-inflammatory, first-in-class synthetic drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs). Celsus’s proprietary drug technology platform is unique and potentially offers an answer to an urgent unmet need: the lack of satisfactory alternatives to corticosteroids in the treatment of a multitude of inflammatory disea

ses. The company has assembled an experienced team that shares its vision and is committed to making it a success. Specialties: Biotechnology, Drug Development, Inflammation, Atopic Dermatitis, Cystic Fibrosis, Ophthalmology

Celsus Therapeutics PLC "Targeting sPLA2 in INFLAMMATION Research: Where We Stand Today" by Gur Roshwalb, M.D., Chief Ex...
09/10/2014

Celsus Therapeutics PLC "Targeting sPLA2 in INFLAMMATION Research: Where We Stand Today" by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics published online at Genetic Engineering & Biotechnology News (GEN).

http://lnkd.in/dqiJhG2

Despite past failures, the search for drugs that can inhibit the inflammatory proteins continues unabated.

09/10/2014

Celsus Therapeutics PLC Celsus Therapeutics Plc Announces First Patient Enrolled in Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis

http://www.celsustx.com/documents/2014-08-06--%20Celsus%20Therapeutics%20Announces%20First%20Patient%20Enrolled%20C012013.pdf

09/10/2014

Celsus Therapeutics PLC "Multi-Functional Anti-Inflammatory Drugs: A Potential Alternative to Steroids," by Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics in the current issue of Western Pennsylvania Healthcare News.

http://lnkd.in/dHXGt7C

Celsus Therapeutics PLC Developing Multi-Functional Anti-Inflammatory Drugs By Gur Roshwalb, M.D., Chief Executive Offic...
09/10/2014

Celsus Therapeutics PLC Developing Multi-Functional Anti-Inflammatory Drugs By Gur Roshwalb, M.D., Chief Executive Officer of Celsus Therapeutics

http://lnkd.in/dPDxnWU

Recent years have witnessed the development of novel, non-steroidal anti-inflammatory drugs termed Multi-Functional Anti-Inflammatory Drugs (MFAIDs) focusing has been on one of the most sought-after pharmaceutical targets in inflammation research: the secretory phospholipase A2 family. Read more...

09/10/2014

Celsus Therapeutics PLC Celsus Therapeutics Announces the Closing of $9.2 Million Public Offering and Full Exercise of Underwriter’s Option to Purchase Additional ADSs

http://www.celsustx.com/documents/2014-02-05--%20Celsus%20Therapeutics%20Announces%20Closing%20of%20Public%20Offering.pdf

Address

24 W 40th Street, Fl 8th
New York, NY
10018

Telephone

(646) 350-0702

Website

Alerts

Be the first to know and let us send you an email when Celsus Therapeutics, Plc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Celsus Therapeutics, Plc:

Shortcuts

Share

Category